Jean-Pierre Garnier, Ph.D. has served on our Board of Radius "since December 2015. Dr. Garnier is currently Chairman of Idorsia Ltd., and was previously Chief Executive Officer of GlaxoSmithKline plc. In addition, Dr. Garnier is also a member of the Board of Directors of United Technologies Corporation, Chairman of the Board of CARMAT, and an Operating Partner at Advent International. Dr. Garnier previously served as Chief Executive Officer of Pierre Fabre S.A. from 2008 to 2010 ...Dr. Garnier was previously Chairman of Cerenis and Alzheon, Inc. and a board member of the Stanford Advisory Council on Interdisciplinary Biosciences, Weill Cornell Medical College and the Dubai International Capital Advisory Board. " 
In December 2015: "Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that Jean-Pierre Garnier, PhD, has been appointed Chairman of the Board of Directors of the company...
"From 2000 to 2008, Dr. Garnier was the first Chief Executive Officer of GlaxoSmithKline, assuming this role upon the merger of SmithKline Beecham and Glaxo Wellcome. Previously, he served as Chief Executive Officer of SmithKline Beecham having joined the company in 1990 as President of Pharmaceuticals for North America. Prior to SmithKline Beecham, Dr. Garnier served as President of Schering-Plough (US). Following his retirement from GlaxoSmithKline, Dr. Garnier was Chief Executive Officer of Pierre Fabre Laboratories and Chairman of Cerenis, a biotechnology company.
Currently, Dr. Garnier is Chairman of the Board of Directors for the Swiss biopharmaceutical company Actelion. He is a director of the United Technologies Corporation and Renault S.A., as well as Operating Partner at Advent International, a private equity firm. He is a member of the board of trustees of Newman’s Own Foundation and a trustee of The Max Planck Institute." 
- Chair, Idorsia Pharmaceuticals (since 2017)
Resources and articles
- ↑ Alzheon Appoints Former GlaxoSmithKline CEO Jean-Pierre Garnier as Chairman of Board of Directors, Alzheon, accessed April 29, 2020.